Back to top
more

Viking Therapeutics (VKTX)

(Delayed Data from NSDQ)

$64.63 USD

64.63
2,237,569

+0.28 (0.44%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $64.52 -0.11 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sundeep Ganoria headshot

Viking (VKTX) Rises 25% in a Month: Should You Buy or Wait?

by Sundeep Ganoria

Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.

Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk

by Zacks Equity Research

Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.

Zacks Investment Ideas feature highlights: Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly

by Zacks Equity Research

Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly have been highlighted in this Investment Ideas article.

Ahan Chakraborty headshot

Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?

by Ahan Chakraborty

Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.

Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates

by Zacks Equity Research

Viking (VKTX) gains 24% on better-than-expected second-quarter 2024 results, along with encouraging updates regarding its pipeline development plans.

The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences

by Zacks Equity Research

Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.

Ahan Chakraborty headshot

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

by Ahan Chakraborty

Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.

Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $50.90, marking a +1.6% move from the previous day.

Sundeep Ganoria headshot

Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?

by Sundeep Ganoria

Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.

Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today

by Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) reachead $50.12 at the closing of the latest trading day, reflecting a +0.56% change compared to its last close.

Sundeep Ganoria headshot

Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data

by Sundeep Ganoria

Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.

Ahan Chakraborty headshot

Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?

by Ahan Chakraborty

Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.

Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's

by Zacks Equity Research

Data from a new study, also published on the JAMA website, shows that patients taking Lilly's (LLY) obesity drug are likely to lose more weight than those taking Novo's drug.

Sundeep Ganoria headshot

NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss

by Sundeep Ganoria

A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.

Sundeep Ganoria headshot

Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?

by Sundeep Ganoria

Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.

Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $47.39, denoting a -0.86% change from the preceding trading day.

Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today

by Zacks Equity Research

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $50.43, marking a -0.41% move from the previous day.

Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $52.10, denoting a -0.69% change from the preceding trading day.

Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $55.99, signifying a +1.78% move from its prior day's close.

Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates

by Zacks Equity Research

GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.

Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results

by Zacks Equity Research

Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.

Here's Why Viking Therapeutics, Inc. (VKTX) Gained But Lagged the Market Today

by Zacks Equity Research

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.26, representing a +0.78% change from its previous close.

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound

by Zacks Equity Research

Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.